METHODS: We retrospectively reviewed the medical records of TACE-naïve patients with multifocal HCC (Child-Pugh class A, up-to-seven out, no prior history of systemic therapy) who underwent whole-liver DDP-H TACE between January 2006 and December 2019.
RESULTS: Sixty patients were included in this study. The median age of the patients was 71 (range, 35-88) years. The median maximum size of tumors was 26 (range, 8-184) mm; 86.7% of patients met the up-to-11 criteria out. The overall survival duration was 30.3 months. At the time of initial evaluation (median, 45 days), the overall response rate was 65.0%; the disease control rate was 86.7% based on the modified response evaluation criteria in solid tumors guideline. Although nine patients\' liver function had deteriorated to Child-Pugh class B at initial evaluation, six of them recovered to Child-Pugh class A. Only three patients (5%) showed permanently impaired liver function.
CONCLUSIONS: Whole-liver DDP-H TACE without lipiodol or beads effectively reduced tumors and preserved liver function.
方法:我们回顾性回顾了TACE初治多灶性HCC患者的病历(Child-PughA级,多达七个,没有系统治疗史),在2006年1月至2019年12月期间接受了全肝DDP-HTACE。
结果:本研究纳入60例患者。患者的中位年龄为71岁(范围,35-88)年。肿瘤的最大尺寸中位数为26(范围,8-184)毫米;86.7%的患者符合多达11个标准。总生存期为30.3个月。在初步评估时(中位数,45天),总缓解率为65.0%;根据实体肿瘤指南中改良的缓解评估标准,疾病控制率为86.7%.尽管9例患者的肝功能在初步评估时已恶化至Child-PughB级,其中6例恢复到Child-PughA级。只有3例患者(5%)表现出永久性肝功能受损。
结论:全肝DDP-HTACE无碘油或珠可有效减少肿瘤并保留肝功能。